iCardio Alliance - TMA | Translational Medicine Academy

INTERNATIONAL CARDIOVASCULAR ALLIANCE TO IMPROVE DISEASE OUTCOMES

The iCARDIO Alliance aims to gather leading cardiovascular societies around the globe as Partner Organizations to improve the quality of cardiovascular care, from prevention and diagnosis to patient follow-up.

VIEW ON-DEMAND | HF GUIDELINES
CONTROVERSIES MEETING

Download program

Download PDF

INTERNATIONAL CARDIOVASCULAR ALLIANCE TO IMPROVE DISEASE OUTCOMES

VIEW ON-DEMAND | HF GUIDELINES
CONTROVERSIES MEETING

Download programme

Who we are

In 2021, TMA decided to expand its mission to developing “Global Implementation Guidelines” to complement the currently available international and national quality guidelines in cardiology and focus on implementation of best practice throughout the world. This project, under the umbrella of the iCARDIO Alliance, aims at filling the need for implementation-focused cascade documents, in particular for its members in low resource settings.

ORGANIZATION OF THE iCARDIO GLOBAL
IMPLEMENTATION GUIDELINES

Each iCARDIO Partner Organization is invited by the Guideline Advisory Board(GAB) to nominate a candidate member for selected guideline author groups as well as to nominate one reviewer (who will be considered as co-author) for each guideline document (or for selected documents, if the number of Partner Organizations is more than 50 in total).

Diversity is reflected across the iCARDIO Alliance.

ORGANIZATIONAL STRUCTURE

The iCARDIO Alliance is an umbrella association bringing together partners from the four corners of the world. These partners all have a vested interest in cardiovascular care and improving implementation of best practice, no matter what the setting is.

The iCARDIO Alliance contributes to the development of the Global Implementation Guidelines under the leadership of the Guideline Advisory Board (GAB). This partnership is administered by TMA which is the reference for any organizational matters.

The Guideline Advisory Board(GAB) puts into place the Task Forces which develop the individual guideline topics. These Task Forces are led by 2-3 Chairs from different continents and 4 to 5 Co-chairs (all together coming from at least 4 continents) and forming the Task Force’s Executive Committee. The writing team (25 to 30 experts maximum, nominated by the Guideline Advisory Board) are composed of no more than 50% of experts coming from Europe and North America.

HOW WE WORK

These Documents are developed using a patient-centric framework. Their authors review existing international, national and regional Guidelines and summarize them with a global three tier approach taking into account the accessibility, availability, and affordability of local resources in their final recommendations. The products of this process are the Global Implementation Guidelines aimed at treating the patients with the best possible care no matter where they are in the world.

Our members

The iCARDIO Alliance brings together scientific societies with a special interest in cardiovascular medicine and related fields, thus promoting a multidisciplinary approach. All partner society members participating in developing the Global Implementation Guidelines are committed, on a voluntary basis, to helping the iCARDIO Alliance with its educational responsibilities.

Our values

The iCARDIO Alliance prides itself in putting forward the importance of ethical behavior, integrity and educational responsibility in the interest of cardiovascular patients throughout the world.

Videos

Watch video

GUIDELINES ADVISORY BOARD MEMBERS

USA

Javed Butler

Australia

John Atherton

Chair - Canada

Shelley Zieroth

Chair - Portugal

Fausto Pinto

USA

William Abraham

China

Yuhui Zhang

India

Vijay Chopra

Greece

Gerasimos Filippatos

Germany

Stefan Anker

Australia

Andrew Coats

Spain

Pepe Zamorano

FUNDING

Funding for the development of the Global Implementation Guidelines, and all other activities of the iCARDIO Alliance, come from the proceeds of educational/scientific initiatives organized by TMA and cover the costs of the dedicated TMA staff, the medical writer, the collaborative editorial platform and the electronic tools such as the DOI management tool. No direct funding for the development of the Guidelines come from the industry but rather come from the proceeds of educational/scientific initiatives of TMA. Chairs, Co-chairs, Task Force Members and Reviewers act as volunteers and therefore, are not compensated for their work on the Documents. Travel expenses for Chairs, Co-chairs, Task Force Members and Reviewers, if there are any, are covered by TMA according to the TMA reimbursement policy.